In the NEJ009 study, the survival benefit of concurrent treatment with gefitinib and pemetrexed-carboplatin chemotherapy with gefitinib alone as a first-line treatment was compared in Japanese patients with advanced NSCLC with EGFR mutations [26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.